1. Clinical & Scientific Overview
Linezolid (TIP-MED-000150, Reference Code [8.22]) is classified under
Antimicrobials — Antibacterial & Antibiotic Agents (Ch 08) as a Oxazolidinone 50S Ribosomal Initiation Complex Inhibitor — ICMR 'Reserve' Group (Schedule H | NLEM 2022 | HIGH-ALERT).
Within the Indian regulatory and compendial framework, it is governed under Schedule H1 Prescription Drug (Mandatory Red-Bordered Rx Warning & 3-Year Register under Rule 65 of Drugs Rules 1945).
Representative Indian Market Examples (Edition 2.7 Ch 08 [8.22], p. 103): Lizolid (Glenmark), Linospan (Cipla), Voxaz (Sun), Zyvox (Pfizer) — Strengths & Dosage Forms: Film-Coated Tablets: 600 mg; Dry Syrup: 100 mg/5 mL; IV Infusion Bag: 600 mg/300 mL (2 mg/mL)
Film-Coated Tablets: 600 mg; Dry Syrup: 100 mg/5 mL; IV Infusion Bag: 600 mg/300 mL (2 mg/mL)
3. Mechanism of Action & Pharmacodynamics
Oxazolidinone 50S Ribosomal Initiation Complex Inhibitor — ICMR 'Reserve' Group (Schedule H | NLEM 2022 | HIGH-ALERT) acting on target receptor/enzyme pathways in Antimicrobials — Antibacterial & Antibiotic Agents (Ch 08): clinical efficacy is mediated via Oxazolidinone 50S Ribosomal Initiation Complex Inhibitor — ICMR 'Reserve' Group (Schedule H | NLEM 2022 | HIGH-ALERT) for Confirmed or strongly suspected MRSA pneumonia or complicated skin/soft-tissue infections, Vancomycin-Resistant Enterococcus (VRE), and MDR/XDR Tuberculosis (BPaLM / longer MDR-TB regimens at 600 mg OD). 100% oral bioavailability (600 mg PO = 600 mg IV)!.
4. Therapeutic Indications & Evidence-Supported Uses
- Confirmed or strongly suspected MRSA pneumonia or complicated skin/soft-tissue infections, Vancomycin-Resistant Enterococcus (VRE), and MDR/XDR Tuberculosis (BPaLM / longer MDR-TB regimens at 600 mg OD)
- 100% oral bioavailability (600 mg PO = 600 mg IV)!
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: MRSA / VRE Infections: 600 mg PO or IV every 12 hours (BD) for 10–14 days (Children <12 yr: 10 mg/kg q8h). MDR-TB Regimen: 600 mg PO Once Daily (often reduced to 300 mg OD after 4–8w) + Pyridoxine (Vit B6) 50–100 mg OD!
Administration & Meal Timing: May be taken with or without food; avoid large amounts of tyramine-rich foods/beverages | Morning & Evening (12-hourly BD for MRSA/VRE; Once Daily for MDR-TB)
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Renal & Hepatic: Parent drug requires no dose adjustment in CKD, but two primary metabolites accumulate 7–8-fold in severe CKD/dialysis, increasing thrombocytopenia risk (monitor platelets twice weekly in CKD!)
Renal & Hepatic: Parent drug requires no dose adjustment in CKD, but two primary metabolites accumulate 7–8-fold in severe CKD/dialysis, increasing thrombocytopenia risk (monitor platelets twice weekly in CKD!)
Renal & Hepatic: Parent drug requires no dose adjustment in CKD, but two primary metabolites accumulate 7–8-fold in severe CKD/dialysis, increasing thrombocytopenia risk (monitor platelets twice weekly in CKD!)
7. Contraindications, Precautions & High-Risk Warnings
- REGULATORY & SAFETY VERIFICATION: Linezolid is a Schedule H prescription drug (NOT listed in Schedule H1 notification G.S.R. 588(E)), classified in WHO/ICMR Reserve group (never dispense empirically for simple boils!). Linezolid is a REVERSIBLE NON-SELECTIVE MONOAMINE OXIDASE INHIBITOR (MAOI)!
Key Clinical Precautions: Renal & Hepatic: Parent drug requires no dose adjustment in CKD, but two primary metabolites accumulate 7–8-fold in severe CKD/dialysis, increasing thrombocytopenia risk (monitor platelets twice weekly in CKD!)
8. Adverse Effects Profile
- Diarrhoea, nausea, headache, metallic taste, tongue discolouration (black hairy tongue), candidiasis
- Time-dependent Reversible Myelosuppression (thrombocytopenia, sideroblastic anaemia, leukopenia — frequent after >10–14 days!), Irreversible Peripheral & Optic Neuropathy (after >28 days), Lactic Acidosis, Serotonin Syndrome
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- CRITICAL SEROTONIN SYNDROME & MAOI HYPERTENSIVE CRISIS: Concomitant SSRIs (Escitalopram, Sertraline, Fluoxetine), SNRIs (Duloxetine, Venlafaxine), TCAs (Amitriptyline), Tramadol, Tapentadol, Dextromethorphan, or Triptans can precipitate fatal SEROTONIN SYNDROME! Sympathomimetic nasal decongestants (Pseudoephedrine, Phenylephrine) cause severe hypertensive crisis!
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: COUNTER CHECKS: (1) Screen medication list for antidepressants (Escitalopram/Sertraline/Duloxetine/Amitriptyline), Tramadol, or cold tablets (Phenylephrine) before dispensing Lizolid/Linospan; (2) Get a weekly blood count (CBC/Platelets) if prescribed for >7–10 days; (3) Report any blurred vision, tingling in feet, or unexplained bruising/vomiting immediately
- Meal & Clock Timing Instruction: May be taken with or without food; avoid large amounts of tyramine-rich foods/beverages (Morning & Evening (12-hourly BD for MRSA/VRE; Once Daily for MDR-TB))
- Missed Dose Protocol: Take as soon as remembered unless within 4h of next dose; never double dose
- Geriatric Dispensing Pearl: Higher rate of Linezolid-induced thrombocytopenia in older adults (especially with CKD); check platelets at Day 7
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Film-Coated Tablets: 600 mg; Dry Syrup: 100 mg/5 mL; IV Infusion Bag: 600 mg/300 mL (2 mg/mL)
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 08 [8.22] (p. 103)
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [8.19]-C63 Imipenem + Cilastatin [FDC] — Broad-Spectrum Parenteral Carbapenem Beta-Lactam Antibiotics — IC
- [8.20]-C64 Erythromycin — Macrolide 50S Ribosomal Protein Synthesis Inhibitors — Potent CYP
- [8.23]-C65 Gentamicin Sulfate — Aminoglycoside 30S Ribosomal Bactericidal Antibiotics (Schedule H
- [8.24]-C66 Ofloxacin — Fourth- & Second-Generation Fluoroquinolone DNA Gyrase / Topoisom
